retatrutide type 2 diabetes phase 2 trial Reta clinical data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in 3 trials for metabolic health — targeting GLP-1, GIP Retatrutide Phase 2: Type 2

Phase High escalation Weeks Weeks 13-16 Weekly Dose 6 mg Notes Phase 3 added this intermediate step

Rotating sites : Regularly switching injection sites helps prevent irritation, scarring, and fat tissue changes (lipodystrophy)

Review describing the physiological role of GLP-1 in the central regulation of feeding behaviour, as well the effects of pharmacological stimulation of GLP-1 pathways leading to alterations in CNS activity, reduced food intake and weight loss in obesity and T2DM

Food and Drug Administration approved the first GLP-1 medications in 2005

A three-month purchase at 15% off effectively gives you two weeks of free medication

How GLP-1 receptor agonists work Lets reel it back in for a sec